Eli Lilly Analyst Price Targets

Wall Street analyst price targets and consensus rating for Eli Lilly (LLY).

Price Target Range — 10 Quarters

Analyst Consensus — 21 Analysts

20Buy

1Hold

Consensus RatingBuy# Analysts21Avg. Consensus PT$1251Upside to Avg. PT-4.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 21, 2026	Leerink Partners	David Risinger	PT Raise	Outperform	$1309→$1316
Oct 12, 2026	RBC Capital	Trung Huynh	Maintained	Outperform	$1500
Oct 8, 2026	Cantor Fitzgerald	Carter Gould	PT Raise	Overweight	$1410→$1440
Oct 7, 2026	Morgan Stanley	Terence Flynn	PT Raise	Overweight	$1419→$1430
Sep 28, 2026	JP Morgan	Chris Schott	PT Raise	Overweight	$1400→$1500
Sep 22, 2026	TD Cowen	Steve Scala	Maintained	Buy	$1250
Sep 18, 2026	Guggenheim	Seamus Fernandez	PT Raise	Buy	$1273→$1284
Sep 10, 2026	HSBC	Rajesh Kumar	PT Raise	Reduce	$850→$940
Aug 7, 2026	Truist Securities	Robyn Karnauskas	PT Raise	Buy	$1370→$1376
Aug 6, 2026	Wells Fargo	Mohit Bansal	PT Raise	Overweight	$1280→$1330
Aug 6, 2026	Cantor Fitzgerald	Carter Gould	PT Raise	Overweight	$1350→$1410
Jul 15, 2026	Citigroup	Geoff Meacham	PT Raise	Buy	$1500→$1600
Jul 14, 2026	Bernstein	Courtney Breen	PT Raise	Outperform	$1300→$1385
Jul 13, 2026	UBS	Michael Yee	PT Raise	Buy	$1250→$1425
Jul 13, 2026	Guggenheim	Seamus Fernandez	PT Cut	Buy	$1235→$1273
Jul 10, 2026	B of A Securities	Jason Gerberry	PT Raise	Buy	$1251→$1334
Jul 8, 2026	Truist Securities	Robyn Karnauskas	PT Raise	Buy	$1281→$1370
Jul 8, 2026	Morgan Stanley	Terence Flynn	PT Raise	Overweight	$1344→$1347
Jul 8, 2026	RBC Capital	Trung Huynh	PT Raise	Outperform	$1250→$1500
Jul 7, 2026	JP Morgan	Chris Schott	PT Raise	Overweight	$1300→$1400

Analyst Ratings News

Top Wall Street Forecasters Revamp Eli Lilly Expectations Ahead Of Q3 Earnings

Eli Lilly reports Q3 earnings Oct. 29; EPS is forecast at $6.67, revenue at $22.62B. New Omvoh data supports ulcerative colitis and Crohn’s treatment.

Avi Kapoor

PRO
Leerink Partners Maintains Outperform on Eli Lilly, Raises Price Target to $1316

Leerink Partners analyst David Risinger maintains Eli Lilly (NYSE:LLY) with a Outperform and raises the price target from $1309 to $1316.

Benzinga Newsdesk

PRO
RBC Capital Reiterates Outperform on Eli Lilly, Maintains $1500 Price Target

RBC Capital analyst Trung Huynh reiterates Eli Lilly (NYSE:LLY) with a Outperform and maintains $1500 price target.

Benzinga Newsdesk

Eli Lilly To Rally Over 21%? Here Are 10 Top Analyst Forecasts For Thursday

Analysts raised targets for Everpure, Eli Lilly and Delek US, while cutting targets for Constellation, Tyler, ArriVent and Netflix.

Avi Kapoor

PRO
Cantor Fitzgerald Maintains Overweight on Eli Lilly, Raises Price Target to $1440

Cantor Fitzgerald analyst Carter Gould maintains Eli Lilly (NYSE:LLY) with a Overweight and raises the price target from $1410 to $1440.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Eli Lilly, Raises Price Target to $1430

Morgan Stanley analyst Terence Flynn maintains Eli Lilly (NYSE:LLY) with a Overweight and raises the price target from $1419 to $1430.

Benzinga Newsdesk

Eli Lilly and Co

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Eli Lilly Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

Top Wall Street Forecasters Revamp Eli Lilly Expectations Ahead Of Q3 Earnings

PRO
Leerink Partners Maintains Outperform on Eli Lilly, Raises Price Target to $1316

PRO
RBC Capital Reiterates Outperform on Eli Lilly, Maintains $1500 Price Target

Eli Lilly To Rally Over 21%? Here Are 10 Top Analyst Forecasts For Thursday

PRO
Cantor Fitzgerald Maintains Overweight on Eli Lilly, Raises Price Target to $1440

PRO
Morgan Stanley Maintains Overweight on Eli Lilly, Raises Price Target to $1430

People Also Watch

People Also Watch

Eli Lilly and Co

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Eli Lilly Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

Top Wall Street Forecasters Revamp Eli Lilly Expectations Ahead Of Q3 Earnings

PROLeerink Partners Maintains Outperform on Eli Lilly, Raises Price Target to $1316

PRORBC Capital Reiterates Outperform on Eli Lilly, Maintains $1500 Price Target

Eli Lilly To Rally Over 21%? Here Are 10 Top Analyst Forecasts For Thursday

PROCantor Fitzgerald Maintains Overweight on Eli Lilly, Raises Price Target to $1440

PROMorgan Stanley Maintains Overweight on Eli Lilly, Raises Price Target to $1430

People Also Watch

People Also Watch

PRO
Leerink Partners Maintains Outperform on Eli Lilly, Raises Price Target to $1316

PRO
RBC Capital Reiterates Outperform on Eli Lilly, Maintains $1500 Price Target

PRO
Cantor Fitzgerald Maintains Overweight on Eli Lilly, Raises Price Target to $1440

PRO
Morgan Stanley Maintains Overweight on Eli Lilly, Raises Price Target to $1430